BioCentury
ARTICLE | Politics & Policy

ABPI sets team for value-based pricing negotiations

August 18, 2012 12:11 AM UTC

The Association of the British Pharmaceutical Industry announced the members of a team that will negotiate with the U.K.'s Department of Health for the country's proposed value-based pricing system. John Kearney, U.K. and Ireland general manager at Amgen Inc. (NASDAQ:AMGN), will chair the group, which will include Peter Butterfield, executive director at Alliance Pharma plc (LSE:APH); Erik van Snippenberg, general manager and SVP for the U.K. at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Jon Emms, managing director for the U.K. at Pfizer Inc. (NYSE:PFE); and Matthew Speers, managing director, British and Irish Isles at UCB Group (Euronext:UCB). ...